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Abstract 
Objective 
To determine the economic impact of the introduction of carbetocin for the prevention of post 
partum haemorrhage (PPH) at caesarean section, compared to oxytocin. 
Study design 
The model is a decision tree conducted from a UK National Health Service perspective. 1500 
caesarean sections (both elective and emergency) were modelled over a 12 month period. Efficacy 
data was taken from a published Cochrane meta-analysis, and costs from NHS Reference costs, the 
British National Formulary and the NHS electronic Medicines Information Tool. A combination of 
hospital audit data and expert input from an advisory board of clinicians was used to inform 
resource use estimates. The main outcome measures were the incidence of PPH and total cost over 
a one year time horizon, as a result of using carbetocin compared to oxytocin for prevention of PPH 
at caesarean section. 
Results  
The use of carbetocin compared to oxytocin for prevention of PPH at caesarean section was 
associated with a reduction of 30 (88 vs 58) PPH events (>500ml blood loss), and a cost saving of 
£27,518. In probabilistic sensitivity analysis, carbetocin had a 91.5% probability of producing better 
outcomes, and a 69.4% chance of being dominant (both cheaper and more effective) compared to 
oxytocin. 
Conclusion 
At list price, the introduction of carbetocin appears to provide improved clinical outcomes along 
with cost savings, though this is subject to uncertainty regarding the underlying data in efficacy, 
resource use, and cost. 
Keywords: Cost-effectiveness, Economic model, carbetocin, postpartum haemorrhage.  
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Main text (Word Count 2496) 
Introduction  
Primary Post Partum Haemorrhage (PPH) is most commonly defined as blood loss of 500ml or more 
from the genital tract within 24 hours of the birth of a baby(1). Uterine atony is the cause of up to 
90% of PPH and is increasing(2). Prophylactic uterotonic drugs are part of the active management of 
the third stage of labour that reduce risk of PPH by 66% when compared with physiological 
management(3), and a World Health Organisation (WHO) study concluded that haemorrhage 
prevention programmes should focus on the use of uterotonic drugs(4). 
The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom currently 
recommend oxytocin (Syntocinon®, Alliance) as the uterotonic drug of choice for PPH prophylaxis: a 
10IU intramuscular dose for vaginal births(5) and a 5IU slow intravenous dose for caesarean 
births(6). Carbetocin (Pabal®, Ferring) is a synthetic analogue of oxytocin, with structural 
modifications that increase its half-life and duration of action(7). A Cochrane review(8) concluded 
that use of carbetocin resulted in a statistically significant reduction in the use of additional 
uterotonic drugs at caesarean section when compared with oxytocin and a numerical reduction in 
the incidence of PPH. Although carbetocin is likely to be at least as clinically effective as oxytocin, it 
is more expensive, with little published evidence on the cost-effectiveness of its use – as highlighted 
by the Cochrane review(8). The data that does exist is conflicting and of variable quality(9) (10). 
In this paper we describe the use of a health economic model constructed to assess the cost-
effectiveness of carbetocin for PPH prophylaxis at caesarean section from the perspective of the UK 
National Health Service. 
 
Methods 
A decision tree was constructed in Microsoft Excel 2010® to model prophylactic doses of 5 IU 
intravenous oxytocin, or a single prophylactic (100µg) dose of intravenous carbetocin at caesarean 
section for PPH prevention. The evaluation was undertaken from a National Health Service 
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perspective, in keeping with UK National Institute for Health and Care Excellence 
recommendations(11). 
The primary outcome measures were the number of PPH events prevented and the impact on total 
cost incurred by a large maternity unit over a one year time horizon, as a result of using carbetocin 
instead of oxytocin for PPH prevention at caesarean section. The study population comprised all 
women undergoing elective and emergency caesarean section. The number of caesarean sections 
performed in the model was set to 1500, based on a unit with approximately 6500 deliveries per (a 
caesarean section rate of about 24%). Hospital-level audit data was used to inform estimates of 
resource use. 
Treatment pathway 
The modelled treatment pathway is shown in Figure 1. Patients undergoing caesarean section 
receive a prophylactic uterotonic drug after their delivery. Despite this prophylaxis, some women 
experience uterine atony requiring additional uterotonic drugs that will prevent PPH in some, but 
not all cases. Patients experience varying volumes of blood loss at caesarean section – in the model 
this is captured in 4 health states – ‘No PPH event’, ‘PPH 500-999ml’, ‘PPH 1000-1499ml’ and “PPH 
>1500ml”. Larger volumes of blood loss are associated with more treatment and resource use, and 
as a result are more expensive. Table 1 shows the inputs to the model by different levels of blood 
loss.  
Patients are monitored in recovery for 2 hours after their caesarean section, as recommended by 
national guidelines(6). Patients requiring additional uterotonic drugs (e.g. 4 hour oxytocin infusion) 
stay in recovery, or on labour ward, for longer. In these areas staff to patient ratios are greater, and 
more medical time is utilised. Patients who experience a large PPH are more likely to require 
postnatal follow up, and for their care to be discussed at a risk management forum. A combination 
of published data and hospital-level data was used in the economic model (Table 2). 
 
Clinical effectiveness 
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Relative clinical efficacy was obtained from a published Cochrane Collaboration meta-analysis of four 
randomised control trials of carbetocin and oxytocin for PPH prophylaxis at caesarean section(8). 
Data used included the rate of PPH and the proportion of patients requiring additional uterotonic 
drugs (Table 3). Point estimates (published means) have been used in the base case, with 
probabilistic estimates also presented, as the Cochrane review concluded that although the 
reduction in the use of additional uterotonic drugs was statistically significant, the estimate for 
differences in PPH rates was not (p=0.086). The use of values (even if statistically insignificant), with 
a confidence interval around their estimates is well established in health economics(12), as such 
estimates provide a the best estimate to the real world, where evidence is not always clear and is 
associated with uncertainty regardless of the significance of the finding. 
During the review of existing literature, we noted that the reporting of PPH categories is 
inconsistent:  the meta-analysis data(8) includes analyses of both “PPH >1000ml” (two studies), and 
“PPH >500ml or as defined by trialist” (all four studies). To account for incomplete reporting, the 
proportion of total PPH events in each blood loss category was interpolated from a cohort study of 
1584 women in the Netherlands, which compared carbetocin and several different dosing regimens 
of oxytocin for PPH prophylaxis during caesarean section(13). Data regarding the distribution of PPH 
events across these categories was provided by the publishing authors. The resulting data for PPH in 
each blood loss category for all efficacy sources is shown in Table 1, with the distribution of 
outcomes assumed to be the same in both arms. 
 
Resource use 
Clinical management and resource use escalates with increasing blood loss. The proportion of cases 
requiring additional uterotonic drugs was derived from clinical effectiveness data shown in Table 3. 
The additional uterotonic drug assumed was 5 IU oxytocin given by slow IV bolus, representing 
recommended clinical practice in the UK(14). This single dose was assigned to patients needing 
7 / 15 
“additional uterotonics”, as not all patients who require additional uterotonic drugs go on to 
experience a PPH.  
The resources required to manage a PPH in each of the categories used in the economic model (500-
999ml, 1000-1499ml and ≥1500ml), was estimated by a multi-professional panel of clinical experts. 
Resource use included the type (and number of doses) of additional drugs needed, as well as staff 
time associated with treatment of the PPH. The resulting assumptions are shown in Table 2. These 
are in line with national guidance on the management of PPH(14).  
Where published estimates were not available, hospital level data (from Southmead Hospital, 
Bristol, UK) was used to improve accuracy of resource use estimates. Data used to inform the model 
included average length of maternal inpatient stay post caesarean, proportion of patients needing a 
blood transfusion, units of red blood cells transfused, and provision of consultant follow-up in the 
first ten postnatal weeks. Each item was also calculated for blood loss in the ranges 0-499ml (no 
PPH), 500-999ml, 1000-1499ml and ≥1500ml (see Table 3).  
 
Unit cost estimates 
Costs were calculated in Pounds Sterling, and were taken from NHS Reference costs, the British 
National Formulary and the NHS electronic Medicines Information Tool (which contains the mean 
price paid for generic pharmaceuticals in the UK). 
 
Utilities 
To provide a common unit of comparison, utilities decrements were used for the differing levels of 
PPH. As no direct utility values were available, estimates for the disutility of gastrointestinal bleeds 
(15) were used, such as a disutility of 0.06 for 7 days for PPH 500-1000ml, a disutility of 0.25 for 10 
days for PPH 1000-1500ml, and a disutility of 0.25 for 14 days for PPH>1500ml.  
 
Results 
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Table 4 contains a breakdown of costs associated with the use of oxytocin or carbetocin for 
prevention of PPH at caesarean section in this model. In the base case, the use of carbetocin shows a 
reduction of 30 PPH events (58 vs 88) and an estimated cost saving of £27,518.41 (£2,085,989 vs 
£2,113,508). This difference is mainly driven by a reduction in the number of PPH events 
(incremental cost saving £35,985) and the resultant reduction in time spent in recovery after 
treatment of PPH (incremental cost saving of £12,783). These savings offset the increased drug cost 
of carbetocin compared to oxytocin (unit price £17.64 v £0.80, which gives an increase of £22,860 
per year). 
Probabilistic sensitivity analysis, which takes into account the uncertainty in input values (both 
clinical and cost) shows carbetocin to be more effective than oxytocin in 91.5% of scenarios, and 
dominant (both cheaper and more effective) in 69.4% of scenarios. When attaching utility values to 
PPH events based on assumed disutilities, carbetocin is cost-effective at a threshold of £20,000 per 
QALY in 70.5% of scenarios (Figure 2). 
 
Discussion 
Main findings 
The model demonstrates that carbetocin is likely to provide superior clinical outcomes (by reducing 
the rate of PPH events), along with a cost saving. However probabilistic analysis illustrates 
uncertainty due to the underlying data, where carbetocin does not provide cost savings (30.4%), and 
does not show cost-effectiveness using the NICE threshold for recommendation (over £20,000 per 
QALY gained, 29.5% of scenarios). 
Strengths and limitations of the study 
The treatment pathway used in the model is in line with national guidelines(5, 6, 14). The results 
should be applicable to most maternity units in the United Kingdom, regardless of size, as well as 
those internationally with similar care pathways. Whilst UK guidelines recommend a single 5IU 
oxytocin dose for PPH prophylaxis, we are aware that practice varies greatly(16, 17), and that there 
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is evidence suggesting that the addition of a postoperative oxytocin infusion may further reduce risk 
of PPH(18) Sarna 1997,as is common in other countries(19) (Mockler, French guideline). This does 
not affect our conclusions however; using a 40IU infusion over 4 hours for all oxytocin patients 
increased the cost saving of carbetocin to £31,118 (an increase of approximately £3,600). 
Our analysis is primarily influenced by the clinical effectiveness data chosen for each scenario. 
Cochrane meta-analysis data was used to inform the base case, which raises the question of the 
methodological differences and clinical heterogeneity between studies. An important difference was 
the variability in the method of IV oxytocin administration in each individual study (20),(21) (22, 23). 
Each study referred to their method of oxytocin infusion as “standard”, suggesting that the routine 
dose and administration method for prophylactic oxytocin differs between settings, and over time. 
Ultimately, a meta-analysis provides the best available clinical evidence whilst also reflecting some 
of the variability in clinical practice. A similar limitation is that adverse events were not included in 
the model; in the absence of a definitive head to head trial and variation in reporting/treatment of 
adverse events in heterogeneous trials would introduce a bias of unknown magnitude and direction. 
This is particularly the case as the treatments are given alongside a complex pathway of 
interventions; isolating the adverse events of PPH prophylaxis would be extremely difficult. 
Although necessary for resource use analysis, the sub-categorisation of PPH by blood volume does 
place arbitrary limits on a continuous outcome. As such, the categories have been created based on 
the literature available, and resources assigned to reflect the mean for patients falling within each 
category. We are mindful that exceedingly large PPHs may incur additional costs such as use of 
Factor VII, admission to Intensive Care, and potentially medico-legal expenses associated with 
litigation, there exist no data however on this rare event and as such these have been omitted from 
our estimates so as not to bias the analysis. A further assumption in the model is that the breakdown 
of PPH events into the different categories is assumed to be identical between the two treatments, 
as is the proportion of patients with additional PPH risk factors such as obesity, prolonged labour 
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and placenta praevia. This is representative of clinical practice – PPH is not treated differently based 
on the prophylactic treatment received. 
The lack of universally adopted categories of PPH in clinical trials use to classify obstetric blood loss 
also causes uncertainty in the clinical data, which is carried through to modelling. Although the most 
commonly used definition of PPH is that quoted by the WHO (loss of >500ml blood from the genital 
tract within 24 hours of birth), the outcomes reported in clinical trials vary considerably, particularly 
for trials involving caesarean section. As trials commonly only report blood loss in one of these 
categories (e.g. “PPH >1000ml”, or PPH “>500ml”), missing category data was accounted for by the 
interpolation of categorical PPH proportions from a large published dataset (13). These data are 
from a large study population in a healthcare system comparable with that of the UK however only 
included elective caesarean sections, whereas PPH, particularly severe PPH, is more common 
following emergency caesarean section(24-26). 
Interpretation in light of existing literature 
A small study (9) performed a financial evaluation alongside a departmental audit in a UK hospital, 
after changing from routine use of oxytocin to carbetocin at elective caesarean section. This was an 
observational study but only contained 24 patients in the oxytocin arm, and 37 patients in the 
carbetocin arm. It concluded that carbetocin was associated with a £18.52 increased cost per 
patient, and no significant clinical benefit. In addition to the small sample size and lack of formal 
methods for adjusting for difference in baseline patient characteristics, it is not clear how these costs 
were estimated, and no formal economic modelling was performed. Similarly a Mexican abstract(10) 
reported an economic evaluation of carbetocin for the prevention of uterine atony in patients with 
risk factors for PPH. This compared carbetocin with oxytocin, and included a total of 152 patients. 
Mode of delivery was not stated, nor were details of any blinding, costs included, or treatment 
pathways used. It concluded that the overall cost per patient treated with carbetocin was 529 USD 
less than those treated with oxytocin (approximately £339 per patient). However without further 
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information about the study, resource use, or the costs included, comparison with our results is not 
meaningful.  
A more useful comparison is with a cost-minimization analysis performed from a Canadian 
healthcare system perspective(27) which investigated the use of carbetocin for prevention of PPH 
during elective caesarean section, with treatment pathways modelled on guidelines from the Society 
of Obstetricians and Gynecologists of Canada. This compared carbetocin with unnamed 
“comparators most commonly encountered in clinical practice”. Rather than using clinical trial data 
the study “assumed that the incidence of PPH was equal between treatment strategies”, which will 
have heavily influenced results and is inconsistent with economic evaluation guidelines(12). This 
analysis reported a per patient cost of $31.95 for carbetocin vs $32.31 for oxytocin. While these 
results are more consistent our results, it is again difficult to draw comparisons due to the limited 
information presented, and assumption of equal efficacy in prevention of PPH (contrary to published 
meta-analytic data). 
 
Conclusions 
This economic evaluation combines the best available clinical effectiveness data for the use of 
oxytocin versus carbetocin during caesarean section for PPH prophylaxis, with UK hospital-level 
resource use data. The model estimates carbetocin is likely to result in better clinical outcomes and a 
modest cost-saving when compared to oxytocin, albeit with substantial uncertainty. 
Whilst the results of this model will help to inform policy makers, further work is needed. The 
current data indicate carbetocin is more effective than oxytocin in reducing the use of additional 
uterotonic drugs, and although existing data indicates a numerical advantage for carbetocin in 
reducing the rate of PPH, this does not reach statistical significance. There exists therefore 
uncertainty in the relative clinical effectiveness of PPH, which we hope will be provided by an 
ongoing randomised control trial (“The IMox Study”, Clinicaltrials.gov NCT02216383). 
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Although carbetocin appears to have a number of advantages in our study (potentially including 
cost), a large randomised trial of the use of these drugs at caesarean section with parallel health 
economic evaluation, is required to conclusively inform practice. Until this has been conducted, the 
evaluation presented here uses the most robust information available and demonstrates that the 
introduction of carbetocin is likely to result in better clinical outcomes and potentially a modest per 
patient cost-saving, albeit with uncertainty. At the very least, it appears that carbetocin use would 
be cost-neutral, meaning decisions regarding its introduction should be based on clinical 
effectiveness. 
 
  
13 / 15 
References 
1. WHO recommendations for the prevention and treatment of post partum haemorrhage. 
World Health Organisation, 2012. 
2. Knight M CW, Berg C, Alexander S, Bouvier-Colle M-H, Ford JB, et al. Trends in postpartum 
hemorrhage in high resource countries: a review and recommendations from the International 
Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9(1):55. 
3. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active versus expectant management 
for women in the third stage of labour. The Cochrane database of systematic reviews. 2011 
(11):CD007412. PubMed PMID: 22071837. Pubmed Central PMCID: PMC4026059. Epub 2011/11/11. 
eng. 
4. Gulmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, Abdel-Aleem H, Festin M, et al. 
Active management of the third stage of labour with and without controlled cord traction: a 
randomised, controlled, non-inferiority trial. Lancet (London, England). 2012 May 5;379(9827):1721-
7. PubMed PMID: 22398174. Epub 2012/03/09. eng. 
5. Excellence NIfHaC. Intrapartum Care for Healthy Women and Babies. 2014. 
6. Excellence NIoHaC. Caesarean Section. National Institute for Health and Clinical Excellence, 
2011. 
7. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. 
European journal of obstetrics, gynecology, and reproductive biology. 2009 Nov;147(1):15-20. 
PubMed PMID: 19616358. Epub 2009/07/21. eng. 
8. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. The 
Cochrane database of systematic reviews. 2012;4:CD005457. PubMed PMID: 22513931. Epub 
2012/04/20. eng. 
9. Higgins L, Mechery J, Tomlinson AJ. Does carbetocin for prevention of postpartum 
haemorrhage at caesarean section provide clinical or financial benefit compared with oxytocin? 
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 
2011 Nov;31(8):732-9. PubMed PMID: 22085065. Epub 2011/11/17. eng. 
10. G Del-Angel-Garcia FG-C, A Nevarez-Sida, P Constantino-Casas. A cost effectiveness study of 
Carbetocine compared to oxytocin for the prevention of uterine atony in patients with risk factors. 
Value in Health. 2006;9(3):A50. 
11. Excellence NIfHaC. Guide to the methods of technology appraisal 2013. 
12. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic 
evaluation of health care technologies. Journal of health economics. 1999 Jun;18(3):341-64. PubMed 
PMID: 10537899. Epub 1999/10/28. eng. 
13. Holleboom CA, van Eyck J, Koenen SV, Kreuwel IA, Bergwerff F, Creutzberg EC, et al. 
Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine 
atony after elective caesarean section in the Netherlands. Archives of gynecology and obstetrics. 
2013 Jun;287(6):1111-7. PubMed PMID: 23329341. Pubmed Central PMCID: PMC3655222. Epub 
2013/01/19. eng. 
14. Prevention and management of post partum haemorrhage. Royal College of Obstetricians 
and Gynaecologists, 2011. 
15. Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N. Cost effectiveness of 
romiplostim for the treatment of chronic immune thrombocytopenia in Ireland. Applied health 
economics and health policy. 2013 Oct;11(5):457-69. PubMed PMID: 23857462. Pubmed Central 
PMCID: PMC3824633. Epub 2013/07/17. eng. 
16. Wedisinghe L, Macleod M, Murphy DJ. Use of oxytocin to prevent haemorrhage at caesarean 
section--a survey of practice in the United Kingdom. European journal of obstetrics, gynecology, and 
reproductive biology. 2008 Mar;137(1):27-30. PubMed PMID: 17544563. Epub 2007/06/05. Eng. 
17. Stephens LC, Bruessel T. Systematic review of oxytocin dosing at caesarean section. 
Anaesthesia and intensive care. 2012 Mar;40(2):247-52. PubMed PMID: 22417018. Epub 
2012/03/16. Eng. 
14 / 15 
18. Murphy DJ, MacGregor H, Munishankar B, McLeod G. A randomised controlled trial of 
oxytocin 5IU and placebo infusion versus oxytocin 5IU and 30IU infusion for the control of blood loss 
at elective caesarean section--pilot study. ISRCTN 40302163. European journal of obstetrics, 
gynecology, and reproductive biology. 2009 Jan;142(1):30-3. PubMed PMID: 18977579. Epub 
2008/11/04. Eng. 
19. Mockler JC, Murphy DJ, Wallace EM. An Australian and New Zealand survey of practice of 
the use of oxytocin at elective caesarean section. The Australian & New Zealand journal of obstetrics 
& gynaecology. 2010 Feb;50(1):30-5. PubMed PMID: 20218994. Epub 2010/03/12. Eng. 
20. Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, et al. Carbetocin versus 
oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a 
double-blind randomised trial. BJOG : an international journal of obstetrics and gynaecology. 2010 
Jul;117(8):929-36. PubMed PMID: 20482535. Epub 2010/05/21. eng. 
21. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum 
hemorrhage after cesarean section: a randomized clinical trial. Archives of gynecology and 
obstetrics. 2009 Nov;280(5):707-12. PubMed PMID: 19229549. Epub 2009/02/21. eng. 
22. Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, et al. Double-blind 
comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. 
American journal of obstetrics and gynecology. 1999 Mar;180(3 Pt 1):670-6. PubMed PMID: 
10076146. Epub 1999/03/17. eng. 
23. Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M, et al. Double-blind, 
randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and 
uterine tone of patients undergoing cesarean section. Journal of perinatology : official journal of the 
California Perinatal Association. 1998 May-Jun;18(3):202-7. PubMed PMID: 9659650. Epub 
1998/07/11. eng. 
24. S Daniel MV, B Simi, A Nazeema. Study of maternal outcome of emergency and elective 
caesarean section in a semi-rural tertiary hospital. NATIONAL JOURNAL OF MEDICAL RESEARCH. 
2014;4(1):14-8. 
25. Ghazi A, Karim F, Hussain AM, Ali T, Jabbar S. Maternal morbidity in emergency versus 
elective caesarean section at a tertiary care hospital. Journal of Ayub Medical College, Abbottabad : 
JAMC. 2012 Jan-Mar;24(1):10-3. PubMed PMID: 23855084. Epub 2012/01/01. eng. 
26. Holm C, Langhoff-Roos J, Petersen KB, Norgaard A, Diness BR. Severe postpartum 
haemorrhage and mode of delivery: a retrospective cohort study. BJOG : an international journal of 
obstetrics and gynaecology. 2012 Apr;119(5):596-604. PubMed PMID: 22313728. Epub 2012/02/09. 
eng. 
27. Millsa F CC, editor A cost-minimization analysis of Carbetocin for the prevention of post 
partum hemorrhage in Canada. 19th Annual International Meeting of International Society For 
Pharmacoeconomics and Outcomes Research; 2014; Montreal. 
 
 
 
Figure and table caption list 
Figure 1: Treatment pathway 
Figure 2: Scatterplot of Monte-Carlo estimates (1000 simulations) 
Table 1: Proportionate spread of PPH events across categories of blood loss 
Table 2: Cost and resource use inputs for PPH events 
15 / 15 
Table 3: Clinical effectiveness estimates used in the economic model  
Table 4: Overall cost as a result of using either oxytocin or carbetocin for prevention of post partum 
haemorrhage at caesarean section 
 
